Strategies to lower low-density lipoprotein cholesterol in metabolic syndrome: Averting the diabetes risk

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 3, 2013, Pages 149-151

  Sheely, Dana ^a   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESEVELAM; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE ESCALATION; DYSLIPIDEMIA; EDITORIAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; INSULIN BLOOD LEVEL; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; FEMALE; FLUOROBENZENES; GLUCOSE INTOLERANCE; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 84877861115     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2013.1503     Document Type: Editorial

References (20)

1. Colbert JD, Stone JA. Statin use and the risk of incident diabetes mellitus: A review of the literature. Can J Cardiol 2012;28:581-589.
2. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
3. Marrs JC. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: Focus on combination therapy with colesevelam HCl. Drugs Aging 2012;29:e1-e12.
4. Preiss D, Sattar N. Pharmacotherapy: Statins and new-onset diabetes-the important questions. Nat Rev Cardiol 2012;9: 190-192.
5. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
6. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. http://www.fda.gov/Drugs/DrugSafety/ ucm293101.htm/. Accessed March 1, 2013.
7. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;275:735-742.
8. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-2564.
9. Preiss D, Sattar N. Statins and the risk of new-onset diabetes; a review of recent evidence. Curr Opin Lipidol 2011;22: 460-466.
10. Jialal I, Smith G. Managing the dyslipidemia of metabolic syndrome: Beyond statin therapy. Metab Syndr Relat Disord 2012;10:159-160.
11. Marx N. Commentary on 'Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis' by Preiss et al. Diab Vasc Dis Res 2012;9:78.
12. Jialal I, Devaraj S. Statin therapy for the metabolic syndrome: The evidence base. Metab Syndr Relat Disord 2009; 7:393-396.
13. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004;33:431-453.
14. The AIM-HIGH Investigator. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
15. Florentin M, Liberopoulos EN, Rizos CV, et al. Colesevelam plus rosuvastatin 5, mg/day versus rosuvastatin 10mg/day alone on marker of insulin resistance in patients with hy-percholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord 2012;e-pub ahead of print. doi:10.1089/met.2012.0103 (PMID:23170931).
16. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 2011;108:1129-1135.
17. Handelsman Y, Goldberg RB, Garvey WT, et al. Coleseve-lam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized, prospective study. Endocr Pract 2010; 16:617-628.
18. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Production): A randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
19. FDA Advisory Committee Background Information: Ezetimibe/Simvastatin and Ezetimibe-SHARP Study. Available at www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM277652.pdf/. Accessed March 1, 2013.
20. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10mg versus up-titration of rosuvastatin in patients with hypercholester-olemia (the ACTE Study). Am J Cardiol 2011;108:523-530.